ArticleEuropean journal of radiology open2026
Diagnostic utility of apparent diffusion coefficient values in cervical cancer staging: A retrospective study.
Article in European journal of radiology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Accurate staging is critical for therapeutic planning, which directly determines prognosis, as management shifts from surgical resection in early stages to concurrent chemoradiation in advanced disease. We aimed to evaluate diagnostic utility of apparent diffusion coefficient (ADC) in staging of cervical cancer. Material and methods: A retrospective study of 146 consecutive patients with histopathologically confirmed cervical cancer, who underwent pelvic MRI with DWI at our tertiary care center was conducted. Two independent radiologists performed tumor staging according to FIGO staging classification and regions of interest were drawn on ADC maps. Spearman's rank correlation was employed to evaluate the relationship between ADC values and age, stage, and tumor size. Diagnostic performance parameters, including sensitivity, specificity, and area under the curve (AUC) were assessed. Results: Median ADC values (×10⁻⁶ mm²/s) decreased significantly with disease progression: stage I, 966 (IQR: 182); stage II, 830 (IQR: 287); stage III, 811 (IQR: 230); and stage IV, 750 (IQR: 231); p < 0.05. Moreover, median ADC values differed significantly between patients with and without parametrial, vaginal, and lymph node involvement. (p-values <0.05). ADC values distinguished tumors of ≥ 4 cm from smaller ones with a sensitivity and specificity of 82.1% and 47.8%, respectively. Parametrial and lymph node involvement were detected using ADC values with sensitivities of 85.0% and 68.8% and specificities of 58.0% and 57.1%, respectively. Conclusion: ADC values could be a reliable tool for facilitating more accurate cervical cancer staging and could inform clinical management and decision-making on therapy intensification or de-escalation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.